Back to News
Market Impact: 0.34

Stifel raises MACOM Technology stock price target on data center growth

MTSIBACMRVL
Corporate EarningsCorporate Guidance & OutlookCompany FundamentalsAnalyst EstimatesAnalyst InsightsTechnology & Innovation

MACOM reported Q2 fiscal 2026 sales of $289.0 million, up 6.4% sequentially and 22.5% year over year, topping Stifel’s $285.0 million estimate. The company also guided Q3 sales to $355.0 million at the midpoint, 15.9% above Q2 and 10.9% above Stifel’s prior forecast, driven by broad-based growth led by Data Center. Stifel raised its price target to $385 from $330 while keeping a Buy rating, implying a 40.0x calendar 2027 P/E multiple.

Analysis

This read-through is less about one beat and more about a continued re-rating of the AI interconnect stack. MACOM’s setup says demand is no longer just “strong”; it is becoming visible enough that suppliers with leverage in data-center content can push margin through mix, utilization, and pricing. That matters because it typically pulls forward ordering from optics customers and widens the gap between vendors with real differentiation and those simply riding volume. The second-order winner is the broader optical/networking ecosystem, but not evenly. If MACOM’s content per rack keeps compounding, component bottlenecks can shift from headline transceivers into adjacent analog/RF and interconnect subcomponents, which is bullish for suppliers with scarce capacity and sticky design-ins, while compressing upside for more commoditized exposure. For MRVL, the implication is supportive but also more demanding: the market will increasingly underwrite execution against an accelerating product cycle, so any hiccup on 1.6T ramp, gross margin, or customer concentration will be punished more than in a slower-growth tape. The main risk is that the multiple expansion is running ahead of the sustainable growth slope. A 40x forward multiple can work if the next 2-3 quarters keep delivering upward revisions, but if AI capex digestion creates a pause, these names can de-rate quickly because the story is crowded and positioning is likely elongated. Near term, the catalyst window is earnings/guidance season over the next 1-2 quarters; over a 6-12 month horizon, the key question is whether growth broadens beyond a few hyperscaler programs or stays concentrated enough to create air pockets. Consensus seems to be treating this as a clean secular winner, but the market may be underestimating how quickly supply catches up once utilization normalizes. That would not break the thesis, but it would cap multiple expansion and shift returns from valuation to fundamentals. In that scenario, the best relative trade is not chasing the highest-beta winner outright, but owning the names with the best combination of pricing power, backlog visibility, and margin inflection while fading the most crowded extension names.